CYRX

• Life Sciences Services revenue grew 15% to $28.0 million; BioStorage/BioServices grew 25% to $5.6 million.
• Adjusted EBITDA from continuing operations was positive $0.4 million in Q2 2026, compared to negative $0.9 million in Q2 2025.
• Loss from continuing operations narrowed to $8.3 million in Q2 2026 from $12.0 million in Q2 2025.
• Supported 779 global clinical trials and 22 commercial cell and gene therapies as of June 30, 2026.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Shareholders ratified Deloitte & Touche LLP as independent auditor for 2026, with 47,014,962 votes for and 21,499 against.
• The advisory say-on-pay proposal was approved, with 39,533,693 votes for and 2,390,915 against.
• An amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares was approved, with 30,110,893 votes for and 12,591,758 against.
• The company filed the amended equity incentive plan as an exhibit to this 8-K.

5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• Commercial cell and gene therapy revenue grew 26% to $9.1 million; supported 766 global clinical trials and 21 approved CGTs as of March 31, 2026.
• Life Sciences Services revenue increased 18% to $26.9 million; Life Sciences Products revenue increased 15% to $20.9 million.
• Gross margin was 45.8% for Q1 2026, up from 45.4% in Q1 2025; adjusted EBITDA from continuing operations improved to negative $0.6 million from negative $2.8 million.
• Company raised full-year 2026 revenue guidance to $192 million-$196 million.
• Net loss attributable to common stockholders was $12.5 million, or $0.25 per share, compared to $14.0 million, or $0.28 per share in Q1 2025.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Total revenue for Q4 2025 was $45.5 million, up 10% year-over-year from $41.5 million in Q4 2024.
• Full-year 2025 revenue was $176.2 million, up 12% from $156.8 million in 2024, exceeding the high end of prior guidance.
• Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025.
• Company guides FY 2026 revenue to $190 million-$194 million, representing 8%-10% growth year-over-year.
• Net income for FY 2025 was $78.3 million, driven by a $112.3 million gain from the CRYOPDP divestiture to DHL.
• Cash, cash equivalents, and short-term investments totaled $411.2 million as of December 31, 2025.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Commercial Cell & Gene Therapy revenue grew 36% year-over-year to $8.3 million.
• Life Sciences Services revenue grew 16% to $24.3 million; Life Sciences Products revenue grew 15% to $20.0 million.
• Gross margin from continuing operations was 48.2% in Q3 2025, up from 45.5% in Q3 2024.
• Company raised full-year 2025 revenue guidance to $170.0-$174.0 million from continuing operations.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Net income for Q2 2025 was $105.2 million, primarily driven by the $117.4 million gain (net of taxes) from the CRYOPDP divestiture.
• Adjusted EBITDA improved to negative $0.9 million in Q2 2025 from negative $5.6 million in Q2 2024.
• Company reaffirmed full-year 2025 revenue guidance of $165 million to $172 million.
• Completed divestiture of CRYOPDP to DHL and launched a strategic partnership with DHL Group.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The transaction includes cash payments of approximately $200 million to Cryoport, comprising $133.0 million for the sale and repayment of ~$77.2 million in intercompany loans.
• Cryoport and DHL entered into a strategic partnership to collaborate on life sciences and healthcare supply chain services, with a focus on APAC and EMEA regions.
• The divestiture is expected to provide a capital infusion and improve Cryoport's growth trajectory and path to sustainable profitability.
• Pro forma financial statements reflecting the disposition are included in the filing.

2.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2025 with 36,599,870 votes for.
• The advisory say-on-pay proposal passed with 31,308,283 votes for and 1,549,637 against.
• Shareholders selected a one-year frequency for future say-on-pay votes (31,819,718 votes for one year).
• The company will hold an annual advisory say-on-pay vote until the next required frequency vote.

5.07 Submission of Matters to a Vote of Security Holders